Evidence map›Paper›PMID 33104883›Full record

ArticleJournal of cancer research and clinical oncology2021

Inactivation of ICAM1 inhibits metastasis and improves the prognosis of Ewing's sarcoma.

Bin Pan, Xiangbo Bu, Menghan Cao, Xin Zhang, Tianqun Huo, Ziang Li, Xiao Gao, Li Jing, Xuanxiang Luo, Hu Feng and 2 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Bin Pan *Department of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Xiangbo Bu *Department of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Menghan Cao *Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Xin ZhangDepartment of Dermatology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, 221000, China.
Tianqun HuoDepartment of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Ziang LiDepartment of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Xiao GaoDepartment of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Li JingDepartment of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Xuanxiang LuoDepartment of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Hu FengDepartment of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China. fenghuxz@163.com.
Feng YuanDepartment of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China. yuanfengxz@yeah.net.
Kaijin GuoDepartment of Orthopedics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China. guokaijinxz@yeah.net.ORCID http://orcid.org/0000-0003-0193-3323
Xuzhou Medical College · CN

Funding

China Postdoctoral start-up fund 2018107007Jiangsu Planned Projects for Postdoctoral Research Funds 2018K176CPostdoctoral Research Foundation of China 2019M651967Science and technology project of yili kazak autonomous prefecture YZ2019D006The Youth Program of National Natural Science Foundation of China 81801213
6 · The paper itself

Abstract

backgroundEwing's sarcoma (ES) is a kind of malignant tumor, which often occurs in the long bone, pelvis, and other bone tissues, as well as some soft tissues. It often occurs in children and adolescents, second only to osteosarcoma and rhabdomyosarcoma. In the past 30 years, little progress has been made on the genomic mechanism of ES metastasis.

methodsThe gene expression sequence of ES metastasis samples was compared with that of primary tumor samples to obtain differentially expressed genes (DEGs). Subsequently, we annotated the gene functions and enriched pathways of DEGs. Additionally, the protein and protein interaction network were constructed to screen key genes that can lead to the metastasis in ES. Then, cell and molecular biology experiments were conducted to verify the results obtained from the bioinformatics analysis. Finally, we assessed the correlation of expression between the key genes EWSR and FLI1, and conducted a survival analysis of ICAM1.

resultsOur study revealed 153 DEGs. Of these, 82 (53.59%) were upregulated and the remaining 71 (46.41%) were downregulated. The bioinformatics analysis showed that ICAM1 was the key gene leading to the invasion and metastasis of ES. Through cell biology and molecular biology experiments, inactivation of ICAM1 inhibited the metastasis of ES cells. The survival and correlation analyses showed that ICAM1 was a risk factor in patients with ES, and that ICAM1 expression was correlated with EWSR and FLI1 expression.

conclusionOur study shows that inactivation of ICAM1 inhibits metastasis and improves the prognosis of ES. Additionally, our findings provide a better understanding of the underlying mechanisms of metastatic ES, a basis for an accurate diagnosis, and therapeutic targets for ES patients.

Indexed as

Bone NeoplasmsCell Line, TumorComputational BiologyHumansIntercellular Adhesion Molecule-1Neoplasm InvasivenessNeoplasm MetastasisOncogene Proteins, FusionPrognosisProtein Kinase C-alphaSarcoma, EwingEWS-FUS protein, humanICAM1 protein, humanIntercellular Adhesion Molecule-1Oncogene Proteins, FusionPRKCA protein, humanProtein Kinase C-alphaBioinformaticsEwing's sarcomaICAM1Metastasis

Identifiers

PMID33104883
PMCPMC11802062
OpenAlexW3093631435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.